S
Sionna Therapeutics
Dedicated to delivering therapies that could be transformational for people living with cystic fibrosis
About Sionna Therapeutics
Sionna Therapeutics is a biotechnology startup that is focused on revolutionizing the treatment of cystic fibrosis (CF). The company is developing innovative small molecule therapies that target the most common genetic mutation in CF patients, known as ΔF508. Their ultimate goal is to normalize CFTR function, which is a protein that helps control the balance of salt and water in the body. When this protein is not functioning properly, it leads to the symptoms of CF.
Sionna operates in the healthcare market, specifically within the realm of genetic diseases. Their clients are primarily patients suffering from cystic fibrosis, a life-threatening genetic disorder that severely damages the lungs and digestive system.
The business model of Sionna Therapeutics is centered around the research, development, and eventual commercialization of their novel therapies. They generate revenue through the successful development and sale of these therapies to healthcare providers who then administer them to CF patients.
The company prides itself on its collaborative approach to drug discovery, with a team that is dedicated to making a positive impact on patients' lives. They are currently in the DC / IND-Enabling stage, which means they are conducting necessary studies and preparing to submit an Investigational New Drug (IND) application to the FDA. This is a crucial step in the process of getting a new drug approved for use in patients.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Feb 2025 | $191M | $191M | Undisclosed | ↗ |
| SERIES COther financing | Mar 2024 | $182M | $728M | Atlas Venture · OrbiMed · Viking Global Investors · Perceptive Advisors | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Sionna Therapeutics is 7.4K monthly website visits, up 12.1% over the last three months. Sionna Therapeutics's team grew 17.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Sionna Therapeutics in the Waltham ecosystem
The Sionna Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
OrbiMed
T. Rowe Price
Atlas Venture
Cystic Fibrosis Foundation
RA Capital Management
The Rise Fund (TPG)- QHQ Healthcare Holdings
Series B and later3 investors entered at this stage
Enavate Sciences
Viking Global Investors
Perceptive Advisors
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sionna Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sionna Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









